Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShort-Term Debt repayments
Ratios

China Pharma Holdings (CPHI) Long-Term Debt Issuances (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Long-Term Debt Issuances for 14 consecutive years, with -$44176.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Long-Term Debt Issuances fell 745.56% year-over-year to -$44176.0, compared with a TTM value of $260299.0 through Sep 2025, up 846.68%, and an annual FY2024 reading of $27353.0, down 10.53% over the prior year.
  • Long-Term Debt Issuances was -$44176.0 for Q3 2025 at China Pharma Holdings, down from $290886.0 in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $932114.0 in Q3 2022 and bottomed at -$3.7 million in Q4 2021.
  • Average Long-Term Debt Issuances over 5 years is -$129569.0, with a median of $6856.0 recorded in 2024.
  • The sharpest move saw Long-Term Debt Issuances plummeted 8352.9% in 2021, then skyrocketed 4145.27% in 2025.
  • Year by year, Long-Term Debt Issuances stood at -$3.7 million in 2021, then soared by 100.19% to $6848.0 in 2022, then grew by 1.42% to $6945.0 in 2023, then dropped by 2.06% to $6802.0 in 2024, then crashed by 749.46% to -$44176.0 in 2025.
  • Business Quant data shows Long-Term Debt Issuances for CPHI at -$44176.0 in Q3 2025, $290886.0 in Q2 2025, and $6787.0 in Q1 2025.